Molecular and Genetic Immune Biomarkers of Primary and Immune-Therapy Induced Hypophysitis: From Laboratories to the Clinical Practice
Articolo
Data di Pubblicazione:
2021
Citazione:
Chiloiro, S., Russo, F., Tartaglione, T., Capoluongo, E. D., Molecular and Genetic Immune Biomarkers of Primary and Immune-Therapy Induced Hypophysitis: From Laboratories to the Clinical Practice, <>, 2021; 11 (10): 1-14. [doi:10.3390/jpm11101026] [https://hdl.handle.net/10807/312456]
Abstract:
Hypophysitis is a rare and potentially life-threatening disease, characterized by an elevated risk of complications, such as the occurrence of acute central hypoadrenalism, persistent hypopituitarism, or the extension of the inflammatory process to the neighboring neurological structures. In recent years, a large number of cases has been described. The diagnosis of hypophysitis is complex because it is based on clinical and radiological criteria. Due to this, the integration of molecular and genetic biomarkers can help physicians in the diagnosis of hypophysitis and play a role in predicting disease outcome. In this paper, we review current knowledge about molecular and genetic biomarkers of hypophysitis with the aim of suggesting a possible integration of these biomarkers in clinical practice.
Tipologia CRIS:
Articolo in rivista, Nota a sentenza
Keywords:
CTLA-4; HLA; MHC; PD-1; anti-pituitary antibodies; cytokines; diabetes insipidus; hypoadrenalism; hypopituitarism; immune-check point inhibitors; ipilimumab; nivolumab
Elenco autori:
Chiloiro, Sabrina; Russo, Filippo; Tartaglione, Tommaso; Capoluongo, Ettore Domenico
Link alla scheda completa:
Link al Full Text:
Pubblicato in: